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ABSTRACT 
The objective of the present study was to formulate solid dispersions (SD) of Ezetimibe toimprove the solubility and 
dissolution rate to facilitate faster onset of action. Ezetimibe is a poorly water soluble BCS class II drug and used as 
a hypolipidemic agent. It has poor bioavailability (35-65%) due to its low dissolution profile in gastro intestinal 
tract. In the present study, eight solid dispersion formulations of Ezetimibe with polymers PEG-4000 and PEG-6000 
were prepared by solvent evaporation and fusion methods.  Solid dispersionformulations were characterized by 
content uniformity, flow properties and in vitro dissolution studies. Present study concluded that the Ezetimibe solid 
dispersion formulations are a suitable approach to improve the solubility and dissolution rate of ezetimibe than pure 
form of drug. 
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INTRODUCTION 
Solubility is an important aspect for oral dosage forms, to deliver requireddrug concentration in systemic circulation 
to produce desired pharmacological response
1
. On an average more than 90 % of available drugs have poor 
solubility, poor permeability, or both
2
. For this reason there is always a need to use high doses of poor soluble drugs 
to achieve minimum effective concentration of drug in systemic circulation
3
. 
There are so many approaches to enhance the solubility of such poorly water-soluble drugs like particle-size 
reduction, salt formation, solubilization, and complexation with β cyclodextrins.  All these methods suffer from one 
or the other drawbacks
4
. Among various approaches, the solid-dispersion technique is the most successful in 
improving the dissolution and bioavailability of poorly soluble, active pharmaceutical ingredients because it is 
simple, economical and advantageous
5
. A solid dispersion can be defined as “dispersion of one or more active 
ingredients in an inert carrier matrix in solid-state”. Solid dispersion refers to a group of solid products consisting of 
at least two different components, generally a hydrophilic matrix and a hydrophobic drug
6
. 
The drug can be dispersed molecularly, in amorphous particles (clusters) or in crystalline particles by various 
methods
7
. It enhances solubility by reducing particle aggregation, eliminating crystalanity, increasing wettability, 
dispersabilty and altering the surface properties of drug particles
8
.  When solid-dispersion is exposed to aqueous 
media the carrier dissolves and drug releases as fine colloidal particles, the resulting enhanced surface area produces 
higher dissolution rate and bioavailability of poorly water soluble drugs
9
. Ezetimibe is a BCS class II drug. 
Ezetimibe is a poorly water soluble drug and act as a hypolipidemic agent
10
. Ezetimibe decreases plasma cholesterol 
levels by inhibiting the cholesterol absorption in the intestine. It has 35-65% of bioavailability due to its low 
dissolution profile in gastro intestinal tract
11
. Ezetimibe binds to a carrier of cholesterol absorption, the NiemannPick 
C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells and in hepatocytes thus decreasing the LDL 
in the body and prevent various life threatening diseases. In the present investigation an attempt has been made to 
increase the dissolution profile of Ezetimibe by solid dispersion
12
.  
The aim of the present study was to prepare solid dispersionsin order to achieve increased dissolution rates. 
Therefore, in the present study, solid dispersions of Ezetimibe were prepared by solvent evaporation technique and 
fusion method. Acetone was selected as a solvent as drug has highest solubility in this solvent.  Acetone is 
categorized under class II solvents, less toxic than other chlorinated solvents can be easily evaporated and recovered 
because of its low boiling point.  
MATERIALS AND METHOD 
Ezetimibe was gift sample from Afrab-chem ltd, Nigeria. PEG 4000 and PEG 6000 were 
obtained from Dana Drugs ltd, Lagos, Nigeria and all other reagents used were of analytical grade. 
Preparation of solid dispersions: 
1. Solvent Evaporation method
13 
Required amount of Ezetimibe was dissolved in 10 ml of acetone. Accuratelyweighed carriers PEG 4000, PEG 6000 
corresponding to different drug: carrier ratio by weight was dispersed in drug solution. The solvent was allowed to 
evaporate on water bath under occasional stirring at temperature of 40-42
o
C in a protected environmental condition 
containing an exhaust system. The dried mass was pulverized and was passed through a mesh sieve of number of 
100. The powder was subsequently dried at 40°C for 3 hours in a tray drier.  
2. Fusion method
14 
 
In fusion method the binary solid dispersions were made using PEG-4000, PEG-6000 as carriers with varying drug: 
carrier ratios by the fusion method.  Solid dispersion of Ezetimibe and carriers were obtained by melting carrier in a 
porcelain dish at 80–85° and to this Ezetimibe added with thoroughmixing for 1‐2 minutes followed by quick 
cooling. The dried mass was then crushed and passes through sieve no.40 to get uniform sized particles. 
Table 1: Composition of solid dispersion formulations of Ezetimibe 
Formulation 
code 
Carrier Drug: 
Carrier 
Method Acetone 
SD1 PEG 4000 1:1 Fusion method q.s. 
SD2 PEG 4000 1:3 Fusion method q.s. 
SD3 PEG 6000 1:1 Fusion method q.s. 
SD4 PEG 6000 1:3 Fusion method q.s. 
SD5 PEG 4000 1:1 Solvent evaporation method q.s. 
SD6 PEG 4000 1:2 Solvent evaporation method q.s. 
SD7 PEG 6000 1:1 Solvent evaporation method q.s. 
SD8 PEG 6000 1:2 Solvent evaporation method q.s. 
 
Solubility studies
15
  
The solubility studies of different Ezetimibe and solid dispersionformulations of Ezetimibe were conducted in 
distilled water and phosphate buffer of 1.2, 6.8 and 7.4 pH.  An excess amount of Ezetimibe solid dispersion was 
weighed and transferred into conical flasks which contain 10 ml of media. The content in conical flask were 
sonicated for 2 hrs  at room temperature, there after the samples were placed on a shaker, agitated at room 
temperature for 48 hrs. After it, the suspensions were filtered through a Whatman filter paper. The filtrate was 
suitably diluted and analyzed spectrophotometrically at a wavelength of 232 nm using a double beam UV-Visible 
spectrophotometer. 
 
Table 2: Solubility study of Ezetimibe and solid dispersion formulations of Ezetimibe  
 Solubility ( µg/ ml) 
Distilled Water 1.2 pH buffer 6.8  pH buffer 7.4  pH buffer 
Pure drug 2.37 ± 0.14 3.37 ± 0.14 4.42 ± 0.09 5.31 ± 0.06 
SD1 22.43 ± 0.25 23.48 ± 0.13 24.57 ± 0.26 25.95 ± 0.14 
SD2 24.59 ± 0.09 26.81 ± 0.26 29.44 ± 0.07 31.59 ± 0.26 
SD3 23.47 ± 0.07 26.64 ± 0.07 28.58 ± 0.42 29.74 ± 0.25 
SD4 33.56 ± 0.11 37.83 ± 0.04 36.46 ± 0.18 39.85 ± 0.16 
SD5 26.87 ± 0.26 28.55 ± 0.08 32.74 ± 0.33 29.73 ± 0.09 
SD6 37.48 ± 0.31 39.51 ± 0.15 40.57 ± 0.41 41.66 ± 0.07 
SD7 29.41 ± 0.16 33.74 ± 0.32 35.83 ± 0.09 36.85 ± 0.14 
SD8 30.46 ± 0.08 36.78 ± 0.42 37.58 ± 0.25 38.72 ± 0.25 
 
CHARACTERIZATION OF SOLID DISPERSIONS 
Percent yield
16 
Percent yield was determined by following formula 
Yield= a/(b+c) X 100 
where, a is the weight of solid dispersion sifted through a  60 number mesh sieve, b is the weight of Ezetimibe taken 
for solid dispersion preparation, and c is the weight of polymer taken for solid dispersion preparation. 
Angle of Repose
17
  
The angle of repose has been used to characterize the flow properties of solids. It is a characteristic related to inter 
particulate friction or resistance to movement between particles. This is the maximum angle possible between 
surface of pile of powder or granules and  
Angle of repose is determined by following formula:  
tan θ= h/r 
Where,  
θ = angle of repose,  h = height of the cone, r = radius of the cone base   
Bulk density
18
  
It is the ratio of total mass of powder to the bulk volume of powder. It was measured by pouring the weighed 
powder into a measuring cylinder and the volume was noted. It is expressed in gm/ ml and is given by  
Bulk density= (Mass of powder)/(Bulk volume of powder) 
 
 
Tapped density
19
  
Tapped density was determined by using graduated cylinder. Anaccurately weighed sample was carefully added to 
the graduated cylinder with the aid of funnel. The initial volume was noted and the sample was tapped on a 
horizontal base. Tapping was continued until no further reduction in sample volume was observed.  
Tapped density= (Mass of powder)/(Tapped volume of powder) 
Carr’s Index20  
It indicates the ease with which a material can be induced to flow and powder compressibility. It is expressed in 
percentage and is given by  
Carr,s Index= (Tapped density-Bulk density)/(Tapped density) x100 
Hausner’s ratio21  
Hausner ratio (Hr) is an indirect index of ease of powder flow. It iscalculated by the following formula:  
Hausner^' s ratio= (Tapped density)/(Bulk density) 
Drug content
22 
Solid dispersions (100 mg) were accurately weighed and dissolved separately in 100 ml of  20 %v/v acetic acid. The 
solution was suitably diluted and the absorbance wasmeasured at 232 nm. Drug content was calculated using the 
regression equation. 
In vitro dissolution studies
23 
Ezetimibe a pure drug and solid dispersions were subjected todissolution test using in-vitro dissolution rate 
apparatus-I of USP XXIV (Basket method). This test was performed using 1000 ml of dissolution medium (0.1N 
HCL) at 37 ± 2 
0
C. Accurately weighed samples (plain drug and surface solid dispersions) of drug were filled in ‘00’ 
size hard gelatin capsule by hand filling method and placed in basket of dissolution apparatus which was rotated at 
50 rpm. A 5 ml aliquot of dissolution medium waswithdrawn and replaced with equal volume of fresh dissolution 
medium at appropriate time intervals and analyzed spectrophotometrically by measuring absorbance at 232 nm.  
 
 
 
         
  Figure 1: % Yield of solid dispersion formulations of Ezetimibe 
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   Figure 2: Dissolution profile of Ezetimibe solid dispersion formulations of batch SD1-SD4 
 
   Figure 3: Dissolution profile of Ezetimibe solid dispersion formulations of batch SD5-SD8 
RESULTS AND DISCUSSION 
The equilibrium solubility data are presented in table 2. The solubility ofEzetimibe powder in distilled water at 37 ± 
0.5°C was 2.37 ± 0.14 µg/ ml, whereas solubility of the solid dispersion formulations were in the range of 322.43-
37.48 µg/ ml. In other aqueous media i.e. in phosphate buffer of pH 1.2, 6.8 and 7.4, there was increased solubility 
of solid dispersion formulations in comparison to pure drug. It was found that as the pH of the media increased, 
there was increase in solubility drug and solid dispersion formulations.These findings suggest that solid dispersions 
had much more enhanced equilibrium solubility as compared with pure drug powder and physical mixtures.  
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Table 3: Different evaluation parameters of solid dispersion formulations of Ezetimibe 
Formulation 
code 
% Yield Bulk density Tapped 
density 
Carr’s 
index 
Hausner’s 
ratio  
 
Angle of 
repose 
(θ) 
% Drug 
content 
SD1 99.06 0.92 0.95 3.15 1.032 22
O
 7' 99.05 
SD2 98.20 0.89 0.93 4.30 1.044 21O 6' 98.15 
SD3 98.62 0.85 0.89 4.49 1.047 23O 9' 99.37 
SD4 99.14 0.83 0.88 5.68 1.060 20O 4' 98.85 
SD5 99.42 0.91 0.93 2.15 1.021 20O 5' 99.07 
SD6 99.42 0.90 0.94 4.25 1.044 25O 8' 99.66 
SD7 98.54 0.86 0.91 5.49 1.058 21O 9' 99.15 
SD8 98.86 0.87 0.92 5.43 1.057 26O 1' 99.18 
 
Calculated percent yield of eight solid dispersion formulations of Ezetimibe lies in range of 98.20 to 99.42 % w/w.  
Out of all the formulation of batch SD6 have shown highest yield (99.42 %) whereas formulation of batch SD2 have 
shown minimum yield 98.20%.    
Solid dispersion formulations of Ezetimibe were characterizedwith respect to angle of repose, bulk density, tapped 
density, Carr’s index, and Hausner’s ratio (table 3). Angle of repose was less than 35° and Carr’s index values were 
less than 21 and Hausner’s ratio was less than 1.25 for all the batches indicating good flow properties. 
The drug content in all Ezetimibe solid dispersion formulations containing PEG 4000 as well as PEG 6000 is above 
than 98.15 % as shown in Table 3. The drug content was found to be minimum (98.15 %) for SD7 whereas SD6 
have shown maximum (99.66 %) drug content. PEG 6000 containing formulations showed better results than PEG 
4000 formulations because of its high molecular weight which are responsible for the formation of fine microcrystal 
and absence of drug clusters.  
Dissolution data of Ezetimibe solid dispersion formulations are reported in Fig.2 and Fig.3. From the result, it can be 
seen that all the prepared solid dispersion showed an enhancement in the dissolution rate of the drug compared to 
plain drug. Solid dispersions prepared by using PEG 4000 showed enhanced dissolution when compared to other 
PEG 6000.  
The rank order of dissolution rate improvement for variou carriers are; PEGS 4000>PEG 6000. 
CONCLUSION 
Eight formulations were prepared by the solvent evaporationmethod and fusion method. All prepared solid 
dispersion formulations showed significantly higher drug dissolution in comparison with pure drug.  In the solid 
dispersion there are many mechanism are  responsible for exhibiting faster release like the decrease in particle size, 
partly to the wettability and to some extent to increase in the solubility ofthe drug due to the solubilising effect of 
carrier used or to the increase in surface area of the drug in the product. From the obtained results it can be 
concluded that solid dispersions improved the dissolution rate ofpoorly soluble drug Ezetimibe.  
The results of the Ezetimibe solid dispersion was indeed promising althoughmore evaluation are needed before it 
can be finally recommended for capsule or tablet dosage form ofEzetimibe. 
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